Page 3 - Natco Pharma

Stocks to watch: Tata Steel, NMDC, PNC Infra, Natco Pharma, MTAR Tech

Stocks to watch on June 19, 2023: From Tata Steel to NMDC, here are the top stocks to watch in Monday's trading session

Natco Pharma to set up subsidiary in Indonesia with investment of $3 mn

Natco Pharma Ltd on Thursday said its board has approved setting up of a subsidiary in Indonesia with an investment of up to USD 3 million (nearly Rs 25 crore) for selling pharmaceutical products in that country. The new subsidiary -- PT. NATCO Lotus Farma -- will be a joint venture with Natco holding 51 per cent and the balance stake 49 per cent by PT. Mitra Medis Exim (MME), a part of Mitra Jaya Group, which is a 40 year old multi-diversified group, as the co-promoter, the company said in a regulatory filing. The company's board approved the proposal at its meeting held on Thursday. Natco will initially invest USD 1 million for a stake of 51 per cent as capital contribution and balance will be invested as and when the funds are required by the subsidiary, it added. PT. NATCO Lotus Farma will be engaged in selling pharmaceutical products in Indonesia, it added. MME is in the business of distribution for active pharmaceutical ingredients and excipients for end-users in Indonesia.

Natco Pharma jumps 4% on filing generic version of oncology drug in US

The drug major filed an abbreviated new drug application (ANDA) for generic versions of Olaparib tablets - 100 mg and 150 mg with the US Food and Drug Administration (USFDA)

Breather for Natco in Novartis cardiac drug case from Delhi High Court

May open floodgates for Indian drugmakers to launch the generic version of the drug as early as next week

Broad-based rally lifts Sensex 578pts, Nifty above 17,800; pharma stks lead

CLOSING BELL: Besides, the Nifty Auto and Private Bank indices advanced 1.7 per cent each

Stocks to Watch: IRCTC, McLeod Russel, Sugar, Adani Ports, Gail, Dish TV

Stocks to Watch Today: Oil related shares are likely to be in focus on Tuesday as the oil ministry sought a review of the windfall profit tax on domestically produced crude oil.

Stocks to Watch: GAIL, Sona BLW, ONGC, Natco Pharma, RIL, Airtel, Vodafone

Stocks to Watch: Blackstone Inc. is seeking to raise as much as Rs 3,180 crore ($400 million) through the sale of shares in Indian automotive component maker Sona Comstar

Sensex leaps 1,163 pts from the day's low, ends 581 pts up; Nifty tops 16K

CLOSING BELL: The winners included Indian Oil Corporation, Sun Pharma, Tata Consumer Products, TCS, Cipla, Shree Cement, NTPC, Tech M, Dr Reddy's Labs, Wipro, Ultratech Cement, and Infosys

Here's why HDFC Securities recommends buying VRL Logistics, Natco Pharma

Logistics stocks have been showing strength on the medium term charts, according to Vinay Rajani of HDFC Securities.

Natco board approves proposal to acquire US-based pharma company

The company's board has approved to acquire Dash Pharmaceuticals through one of its subsidiary units, it said

Natco Pharma launches novel drug for colorectal, gastric cancer

Natco Pharma on Thursday said it has launched a novel fixed-dose combination of Trifluridine and Tipiracil, used to treat advanced colorectal and gastric cancer, in the country. The company has launched the product under the brand name Tipanat in a pack of 20 tablets in a bottle, Natco Pharma said in a regulatory filing. Tipanat is a novel antineoplastic nucleoside analog indicated for the treatment of advanced colorectal and gastric cancer. In India, around 1,25,000 new cases of the above-mentioned cancers are reported every year. Tipanat is of high importance in not only extending survival but also in preserving the quality of life in the late lines of treatment which is currently an unmet medical need, the drug maker said. The company said it has launched the medication at an affordable price.

Dr Reddy's, Natco Pharma launch generic cancer drug in Canada

Dr Reddy's Laboratories and Natco Pharma on Thursday said they have launched generic capsules used in the treatment of multiple myeloma and myelodysplastic syndrome patients in the Canadian market.

Natco Pharma slips 6% as Delhi HC allows injunction application by FMC Corp

The Hon'ble High Court of Delhi today orally pronounced judgment in the interim injunction application filed by FMC Corporation on CTPR

Natco Pharma surges 20%, hits new high on USFDA nod for cancer drug

The company has received approval from the US health regulator for the generic version of Celgene's multiple myeloma drug, Revlimid (Lenalidomide) capsules in the US

Natco gets approval for emergency use of Baricitinib for Covid-19 treatment

Natco Pharma has received emergency use approval for Baricitinib tablets, for the treatment of Covid-19 positive patients, from the Central Drugs Standard Control Organization (CDSCO) in India

Natco Pharma gains 4% on emergency use approval for Covid-19 medicine

The company has received Emergency Use approval for Baricitinib tablets, 1mg, 2mg and 4mg strengths from Central Drugs Standard Control Organization (CDSCO) in India

Natco Pharma rallies 7% as firm seeks nod for Covid medicine Molnupiravir

Pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of Covid-19 replication

Covid: Natco Pharma seeks approval for Molnupiravir capsules phase 3 trials

Natco Pharma Limited on Monday said it applied to the Central Drugs Standard Control Organisation (CDSCO) for approval of Phase-III clinical trial of Molnupiravir Capsules

Natco Pharma's board approves acquiring 1% in its Canadian subsidiary

Drug major Natco Pharma on Friday said its board has approved acquiring about 1 per cent stake in its Canadian subsidiary

Natco Pharma Q2 net profit rises 73% to Rs 204 crore on robust sales

Consolidated total income of the company stood at Rs 827.9 crore for the quarter under consideration